PMID- 17598372
OWN - NLM
STAT- MEDLINE
DCOM- 20070809
LR  - 20190608
IS  - 0301-0430 (Print)
IS  - 0301-0430 (Linking)
VI  - 67
IP  - 6
DP  - 2007 Jun
TI  - Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in 
      hemodialysis patients.
PG  - 366-73
AB  - AIMS: Anemia is a well-known side effect of interferon therapy since interferons 
      are potent inhibitors of erythropoiesis. The aim of this study was to compare the 
      anemia associated with pegylated interferon (PEG-IFN) (alpha2a versus alpha2b 
      therapy in hemodialysis patients (HD) with chronic hepatitis C. METHODS: In order 
      to study the anemia, doses of erythropoietic growth factors (EGF), hemoglobin 
      (Hb) and erythropoietin resistance index (ERI) were compared at baseline and 
      after PEG-IFN-alpha2a or alpha2b therapy in 16 HD patients with chronic C 
      hepatitis. Pharmacokinetic studies were performed in 4 of those treated with 
      PEG-IFN-alpha2b and 2 patients treated with PEG-IFN-alpha2a. Secondary end-points 
      were viral response and serious adverse events. RESULTS: At 4-6 months after the 
      beginning of therapy, both PEG-IFN-alpha induced a significant increment in the 
      erythropoietin resistance index. This increment was significantly higher in 
      patients treated with PEG-IFN-alpha2a when compared with alpha2b (45 vs 9.9, p = 
      0.012). The pharmacokinetics of PEG-IFN-alpha2a and alpha2b in HD patients were 
      different, the C(max), C(min) and the area under the serum concentration time 
      curve, were all higher in patients treated with PEG-IFN-alpha2a compared with 
      PEG-INF-alpha2b. Discontinuation of therapy occurred in 2 (28.5%) of the 7 
      patients in the PEG-IFN-alpha2a group and in 4 (44%) of the 9 patients in the 
      PEG-IFN-alpha2b group. Three (42%) subjects in the alpha2a group and 5 (55%) in 
      the alpha2b group had a response at the end of the 48 weeks of therapy. In 4 
      (44.4%) of the 9 patients treated with alpha2b the viral response was sustained. 
      CONCLUSIONS: In summary, patients treated with PEG-IFN-alpha2a have a major 
      inhibitory effect on erythropoiesis. This could be explained by the different 
      pharmacokinetic properties of PEG-IFN-alpha2a and alpha2b. Further studies are 
      needed to clarify how these findings influence the efficacy, safety and 
      cost-effectiveness of the PEG-IFN-alpha2.
FAU - Espinosa, M
AU  - Espinosa M
AD  - Servicio de Nefrologia, Hospital Universitario Reina Sofia, Cordoba, Spain. 
      espinosahe@supercable.es
FAU - Arenas, M D
AU  - Arenas MD
FAU - Aumente, M D
AU  - Aumente MD
FAU - Barril, G
AU  - Barril G
FAU - Buades, J M
AU  - Buades JM
FAU - Aviles, B
AU  - Aviles B
FAU - Carretero, D
AU  - Carretero D
FAU - Alvarez-Lara, M A
AU  - Alvarez-Lara MA
FAU - Carnicer, F
AU  - Carnicer F
FAU - Martin-Malo, A
AU  - Martin-Malo A
FAU - Aljama, P
AU  - Aljama P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Nephrol
JT  - Clinical nephrology
JID - 0364441
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - G8RGG88B68 (peginterferon alfa-2b)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anemia/*chemically induced
MH  - Antiviral Agents/adverse effects
MH  - Female
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/*adverse effects/blood/pharmacokinetics
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/*adverse effects/pharmacokinetics
MH  - Recombinant Proteins
MH  - *Renal Dialysis
EDAT- 2007/06/30 09:00
MHDA- 2007/08/10 09:00
CRDT- 2007/06/30 09:00
PHST- 2007/06/30 09:00 [pubmed]
PHST- 2007/08/10 09:00 [medline]
PHST- 2007/06/30 09:00 [entrez]
AID - 10.5414/cnp67366 [doi]
PST - ppublish
SO  - Clin Nephrol. 2007 Jun;67(6):366-73. doi: 10.5414/cnp67366.